Next generation of antibody therapy for cancer
Monoclonal antibodies (mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases. To date, 15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications. The selectivity and specificity, the uni...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Sun Yat-sen University Cancer Center
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013394/ |
| id |
pubmed-4013394 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-40133942014-05-15 Next generation of antibody therapy for cancer Zhu, Zhenping Yan, Li Review Monoclonal antibodies (mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases. To date, 15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications. The selectivity and specificity, the unique pharmacokinetics, and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs. mAb-based regimens have brought clinical benefits, including improvements in overall survival, to patients with a variety of cancers. Many challenges still remain, however, to fully realize the potential of these new medicines. With our further understanding of cancer biology, mechanism of antibody action, and advancement of antibody engineering technologies, many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics. Carefully designed and engineered, they retain the advantage of specificity and selectivity of original antibodies, but in the meantime acquire additional special features such as improved pharmacokinetics, increased selectivity, and enhanced anticancer efficacy. Promising clinical results are being generated with these newly improved antibody-based therapeutics. Sun Yat-sen University Cancer Center 2011-05 /pmc/articles/PMC4013394/ /pubmed/21527062 http://dx.doi.org/10.5732/cjc.011.10123 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Zhu, Zhenping Yan, Li |
| spellingShingle |
Zhu, Zhenping Yan, Li Next generation of antibody therapy for cancer |
| author_facet |
Zhu, Zhenping Yan, Li |
| author_sort |
Zhu, Zhenping |
| title |
Next generation of antibody therapy for cancer |
| title_short |
Next generation of antibody therapy for cancer |
| title_full |
Next generation of antibody therapy for cancer |
| title_fullStr |
Next generation of antibody therapy for cancer |
| title_full_unstemmed |
Next generation of antibody therapy for cancer |
| title_sort |
next generation of antibody therapy for cancer |
| description |
Monoclonal antibodies (mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases. To date, 15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications. The selectivity and specificity, the unique pharmacokinetics, and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs. mAb-based regimens have brought clinical benefits, including improvements in overall survival, to patients with a variety of cancers. Many challenges still remain, however, to fully realize the potential of these new medicines. With our further understanding of cancer biology, mechanism of antibody action, and advancement of antibody engineering technologies, many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics. Carefully designed and engineered, they retain the advantage of specificity and selectivity of original antibodies, but in the meantime acquire additional special features such as improved pharmacokinetics, increased selectivity, and enhanced anticancer efficacy. Promising clinical results are being generated with these newly improved antibody-based therapeutics. |
| publisher |
Sun Yat-sen University Cancer Center |
| publishDate |
2011 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013394/ |
| _version_ |
1612086370278309888 |